Swedish Orphan Biovitrum Shares Fall After Cutting Outlook

Swedish Orphan Biovitrum AB fell the most in more than a year in Stockholm trading after cutting its full-year forecast.

Swedish Orphan said sales will increase by 1 percent to 4 percent compared with its earlier forecast of 8 to 10 percent, because of weaker sales than expected in Europe. Shares in the Stockholm-based drugmaker fell as much as 8.2 percent, the steepest decline since July 2009, and were down 1.90 kronor, or 4.6 percent, to 39.50 kronor at 9:14 a.m. local time.